Literature DB >> 3900213

Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

S E Ettinghausen, E H Lipford, J J Mulé, S A Rosenberg.   

Abstract

We previously reported that the adoptive transfer of lymphokine-activated killer (LAK) cells plus repetitive injections of recombinant interleukin 2 (IL 2) produced a marked reduction in established pulmonary metastases from a variety of murine sarcomas. The requirement for the exogenous administration of IL 2 prompted a subsequent examination of the role of IL 2 in the in vivo function of transferred LAK cells. The in vivo proliferation and migration patterns of lymphoid cells in C57BL/6 mice were examined after i.v. transfer of LAK cells alone, i.p. injection of IL 2 alone, or the combination of LAK cells and IL 2. A model for in vivo labeling of the DNA of dividing cells was used in which mice were injected with 5-[125I]-iodo-2'-deoxyuridine (125IUdR) and, 20 hr later, their tissues were removed and were counted in a gamma analyzer. A proliferation index (PI) was calculated by dividing the mean cpm of organs of experimentally treated mice by the mean cpm of organs of control mice. In animals given LAK cells alone, the lungs and liver demonstrated little if any uptake of 125IUdR above saline-treated controls (PI = 2.5 and 0.8, respectively, on day 5), whereas the same organs of mice receiving 6000 U of IL 2 alone displayed higher radiolabel incorporation (PI = 7.1 and 5.9, respectively). When mice were given LAK cells plus 6000 U of IL 2, their tissues showed an additional increase in 125IUdR uptake. In the spleen, kidneys, and mesenteric lymph nodes, IL 2 treatment alone (6000 U) produced elevated PI values that were not, however, additionally increased if LAK cells were also administered. To separate the stimulatory effects of IL 2 on host lymphocyte proliferation from similar IL 2 effects on injected LAK cells, these studies were repeated in mice immunosuppressed by 500 rad total body irradiation. Pre-irradiation of the host sufficiently reduced endogenous lymphoid expansion stimulated by IL 2 so as to allow the demonstration that IL 2 also induced the proliferation of the transferred LAK cells. A variety of studies confirmed that the injected LAK cells were actively proliferating in tissues in vivo under the influence of IL 2. Substitution of "normal" LAK cells with fresh and cultured (without IL 2) splenocytes, or irradiated LAK cells did not result in increased 125IUdR uptake in tissues. Histologic studies corroborated the findings of the 125IUdR incorporation assays and revealed extensive lymphoid proliferation in irradiated mice receiving LAK cells plus IL 2.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900213

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Long-term culture of human LAK cells.

Authors:  U Testa; E Montesoro; D Bulgarini; G Isacchi; G Mastroberardino; F Calabresi; C Peschle
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

3.  Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells.

Authors:  K Oomori; Y Kikuchi; M Miyauchi; T Kita; I Iwano; I Kizawa; J Hirata; E Kuki
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.

Authors:  A A Maghazachi
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

6.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 7.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

8.  Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.

Authors:  R Agah; H Shau; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.

Authors:  M Harada; G Matsuzaki; Y Shinomiya; S Kurosawa; O Ito; T Okamoto; M Takenoyama; H Sumitika; Y Nishimura; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

Review 10.  Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors:  Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal:  Neurosurg Clin N Am       Date:  2012-07       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.